Source: Evaluate Pharma, World Obesity Federation, Putnam Analysis Q2, 2025 Unmet Needs and Potential Differentiation Levers Despite extraordinary promise, there are still unmet needs that biopharma companies can target to address: GI Tolerability The most common GI adverse events (nausea, vomiting, and diarrhea) often lead to therapy discontinuation
GLP-1 medications are not quick fixes
If you travel frequently for work, live in unstable housing situations, or otherwise lack reliable refrigeration, maintaining these medications could be challenging
No, GIP does not significantly slow gastric emptying
Structurally similar to fructose, allulose provides approximately 0.4 kilocalories per gramabout 10% of the energy content of regular sugarand is minimally metabolised by the human body
Muscle loss and bone weakening Numerous studies have documented that rapid weight loss from Ozempic and other medications can cause significant muscle loss, especially in people who dont increase their protein intake